GlaxoSmithKline said on Monday that the US Food and Drug Administration has approved its Priorix vaccine for measles, mumps and rubella in people aged 12 months and older.
Priorix is currently licenced in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand, with more than 800 million doses distributed to date.
Judy Stewart, senior vice president and head of US vaccines at GSK, said: “We’re proud to make Priorix available in the US for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases and to further strengthen offerings in our paediatric vaccine portfolio.”
Temi Folaranmi, MD, vice president and vaccines therapeutic area head, US Medical Affairs, GSK, said: “Outbreaks of measles in recent years demonstrate how quickly diseases can return without widespread immunisation. Missed vaccinations during the pandemic makes children even more vulnerable to vaccine-preventable diseases like measles.
“Making Priorix available to patients in the US will ensure health care professionals have more than one option for this critical vaccine as they work to catch their patients up on recommended vaccinations.”
